4164.TW
CHC Healthcare Group [4164.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4164.TW Stock Summary
Top 10 Correlated ETFs
4164.TW
Top 10 Correlated Stocks
4164.TW
In the News
4164.TW Financial details
Company Rating
Strong Buy
Market Cap
9.9B
Income
418.87M
Revenue
3.88B
Book val./share
39.12
Cash/share
12.28
Dividend
1.97
Dividend %
3.35%
Employees
160
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
32.43
Forward P/E
-
PEG
21.08
P/S
2.97
P/B
1.57
P/C
4.72
P/FCF
-81.7
Quick Ratio
1.93
Current Ratio
2.51
Debt / Equity
0.81
LT Debt / Equity
0.68
-
-
EPS (TTM)
2.55
EPS next Y
-
EPS next Q
-
EPS this Y
15.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.06%
Revenue last 5Y
5.62%
Revenue Q/Q
96.98%
EPS Q/Q
369.23%
-
-
-
-
SMA20
-
SMA50
1.72%
SMA100
-6.35%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
5%
ROC
0.04%
Gross Margin
28%
Oper. Margin
15%
Profit Margin
9%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
52.0-75.7
52W High
-22.67%
52W Low
+11.54%
RSI
39
Rel Volume
0.54
Avg Volume
889.89K
Volume
478.9K
Perf Week
-3.65%
Perf Month
-3.17%
Perf Quarter
0.17%
Perf Half Y
-3.33%
-
-
-
-
Beta
0.413
-
-
Volatility
1.4%, 1.29%
Prev Close
1.4%
Price
58
Change
3.02%
4164.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 21.12 | 17.63 | 15.54 | 18.43 | 23.58 | |
| Net income per share | 2.83 | 2.53 | 2.43 | 2.21 | 2.55 | |
| Operating cash flow per share | 8.52 | 6.32 | 4.41 | 4.07 | 5.85 | |
| Free cash flow per share | 6.05 | 1.34 | 1.14 | -0.16 | 2.35 | |
| Cash per share | 11.56 | 12.24 | 12.22 | 10.66 | 12.32 | |
| Book value per share | 36.95 | 40.34 | 38.75 | 38.06 | 39.27 | |
| Tangible book value per share | 36.92 | 40.29 | 36.19 | 35.9 | 37.36 | |
| Share holders equity per share | 36.95 | 40.34 | 38.75 | 38.06 | 39.27 | |
| Interest debt per share | 19.14 | 28.02 | 32.09 | 31.65 | 32.21 | |
| Market cap | 5.62B | 5.73B | 5.97B | 7.03B | 10.1B | |
| Enterprise value | 6.97B | 8.34B | 9.46B | 10.59B | 13.41B | |
| P/E ratio | 14.23 | 15.65 | 15.66 | 19.71 | 24.11 | |
| Price to sales ratio | 1.91 | 2.24 | 2.45 | 2.36 | 2.6 | |
| POCF ratio | 4.73 | 6.26 | 8.62 | 10.7 | 10.49 | |
| PFCF ratio | 6.65 | 29.52 | 33.43 | -270.58 | 26.1 | |
| P/B Ratio | 1.09 | 0.98 | 0.98 | 1.14 | 1.56 | |
| PTB ratio | 1.09 | 0.98 | 0.98 | 1.14 | 1.56 | |
| EV to sales | 2.36 | 3.26 | 3.88 | 3.56 | 3.46 | |
| Enterprise value over EBITDA | 7.36 | 8.48 | 9.32 | 10 | 10.79 | |
| EV to operating cash flow | 5.86 | 9.11 | 13.65 | 16.13 | 13.94 | |
| EV to free cash flow | 8.25 | 42.92 | 52.92 | -407.76 | 34.67 | |
| Earnings yield | 0.07 | 0.06 | 0.06 | 0.05 | 0.04 | |
| Free cash flow yield | 0.15 | 0.03 | 0.03 | 0 | 0.04 | |
| Debt to equity | 0.5 | 0.68 | 0.82 | 0.82 | 0.81 | |
| Debt to assets | 0.23 | 0.35 | 0.4 | 0.39 | 0.38 | |
| Net debt to EBITDA | 1.43 | 2.65 | 3.43 | 3.37 | 2.67 | |
| Current ratio | 1.15 | 3.31 | 2.55 | 3.65 | 3.04 | |
| Interest coverage | 6.84 | 6.94 | 8.86 | 7.85 | 7.29 | |
| Income quality | 2.5 | 1.97 | 1.41 | 1.36 | 1.72 | |
| Dividend Yield | 0.04 | 0.05 | 0.05 | 0.05 | 0.03 | |
| Payout ratio | 0.63 | 0.77 | 0.82 | 0.91 | 0.78 | |
| Sales general and administrative to revenue | 0.06 | 0.08 | 0.1 | 0.08 | 0.06 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.05 | 0.05 | 0.05 | |
| Capex to operating cash flow | -0.29 | -0.79 | -0.74 | -1.04 | -0.6 | |
| Capex to revenue | -0.12 | -0.28 | -0.21 | -0.23 | -0.15 | |
| Capex to depreciation | -0.84 | -1.64 | -1.12 | -1.37 | -0.97 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 48.49 | 47.9 | 46.03 | 43.5 | 47.44 | |
| ROIC | 0.06 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Return on tangible assets | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Graham Net | -21.5 | -17.7 | -19.28 | -20.14 | -19.67 | |
| Working capital | 460.44M | 2.43B | 2.3B | 2.8B | 2.91B | |
| Tangible asset value | 5.16B | 5.84B | 5.68B | 5.79B | 6.14B | |
| Net current asset value | -2.38B | -2.06B | -2.47B | -2.58B | -2.51B | |
| Invested capital | 0.5 | 0.68 | 0.82 | 0.82 | 0.81 | |
| Average receivables | 1.42B | 1.4B | 1.46B | 1.56B | 1.64B | |
| Average payables | 218.06M | 186.42M | 176.21M | 262.62M | 350.81M | |
| Average inventory | 464.83M | 376.68M | 317.64M | 424.76M | 566.7M | |
| Days sales outstanding | 173.22 | 199.4 | 228.47 | 195.23 | 159.89 | |
| Days payables outstanding | 37.44 | 32.37 | 45.8 | 57.38 | 48.84 | |
| Days of inventory on hand | 74.85 | 66.41 | 73.82 | 93 | 78.68 | |
| Receivables turnover | 2.11 | 1.83 | 1.6 | 1.87 | 2.28 | |
| Payables turnover | 9.75 | 11.28 | 7.97 | 6.36 | 7.47 | |
| Inventory turnover | 4.88 | 5.5 | 4.94 | 3.92 | 4.64 | |
| ROE | 0.08 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Capex per share | -2.46 | -4.98 | -3.27 | -4.23 | -3.5 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.31 | 4.95 | 5.39 | 4.46 | 8.8 | |
| Net income per share | 0.52 | 0.49 | 0.58 | 0.26 | 1.22 | |
| Operating cash flow per share | 1.24 | -0.98 | 1.26 | 1.38 | 4.14 | |
| Free cash flow per share | 0.58 | -1.66 | -0.21 | 0.55 | 3.63 | |
| Cash per share | 10.65 | 10.32 | 9.49 | 8.48 | 12.28 | |
| Book value per share | 38.02 | 37.16 | 37.36 | 37.74 | 39.12 | |
| Tangible book value per share | 35.86 | 35.31 | 35.6 | 36.02 | 37.22 | |
| Share holders equity per share | 38.02 | 37.16 | 37.36 | 37.74 | 39.12 | |
| Interest debt per share | 31.29 | 33 | 31.41 | 31.67 | 31.68 | |
| Market cap | 7.04B | 11.15B | 11.63B | 10.11B | 10.14B | |
| Enterprise value | 10.6B | 14.93B | 15.32B | 14.05B | 13.45B | |
| P/E ratio | 21.02 | 35.17 | 30.42 | 58.44 | 12.62 | |
| Price to sales ratio | 8.2 | 13.93 | 13.12 | 13.71 | 6.98 | |
| POCF ratio | 35.02 | -70.41 | 55.91 | 44.12 | 14.83 | |
| PFCF ratio | 75.68 | -41.52 | -332.16 | 111.13 | 16.91 | |
| P/B Ratio | 1.15 | 1.86 | 1.89 | 1.62 | 1.57 | |
| PTB ratio | 1.15 | 1.86 | 1.89 | 1.62 | 1.57 | |
| EV to sales | 12.35 | 18.65 | 17.29 | 19.05 | 9.26 | |
| Enterprise value over EBITDA | 40.15 | 53.87 | 50.5 | 59.94 | 31.41 | |
| EV to operating cash flow | 52.75 | -94.25 | 73.67 | 61.29 | 19.68 | |
| EV to free cash flow | 114 | -55.59 | -437.69 | 154.37 | 22.44 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.02 | |
| Free cash flow yield | 0.01 | -0.02 | 0 | 0.01 | 0.06 | |
| Debt to equity | 0.82 | 0.88 | 0.84 | 0.84 | 0.81 | |
| Debt to assets | 0.39 | 0.4 | 0.38 | 0.39 | 0.38 | |
| Net debt to EBITDA | 13.5 | 13.63 | 12.18 | 16.79 | 7.74 | |
| Current ratio | 3.65 | 2.17 | 2.37 | 2.51 | 3.04 | |
| Interest coverage | 6.67 | 6.32 | 6.85 | 3.67 | 12.34 | |
| Income quality | 1.78 | -1.45 | 1.58 | 3.8 | 2.65 | |
| Dividend Yield | 0 | 0 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0 | 0 | 7.51 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.06 | 0.08 | 0.05 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Capex to operating cash flow | -0.54 | 0.7 | -1.17 | -0.6 | -0.12 | |
| Capex to revenue | -0.13 | -0.14 | -0.27 | -0.19 | -0.06 | |
| Capex to depreciation | -0.77 | -0.76 | -1.64 | -0.92 | -0.56 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 21.05 | 20.25 | 22.1 | 14.9 | 32.72 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0 | 0.02 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0 | 0.02 | |
| Graham Net | -20.12 | -23.58 | -22.3 | -21.95 | -19.59 | |
| Working capital | 2.8B | 2.17B | 2.35B | 2.37B | 2.91B | |
| Tangible asset value | 5.79B | 5.71B | 5.86B | 5.96B | 6.14B | |
| Net current asset value | -2.58B | -3.01B | -2.84B | -2.76B | -2.51B | |
| Invested capital | 0.82 | 0.88 | 0.84 | 0.84 | 0.81 | |
| Average receivables | 1.55B | 1.61B | 1.67B | 1.67B | 1.66B | |
| Average payables | 280.37M | 283.96M | 302.93M | 377.53M | 383.64M | |
| Average inventory | 472.91M | 608.95M | 739.43M | 847.97M | 756.26M | |
| Days sales outstanding | 166.78 | 182.09 | 173.86 | 197.52 | 105.2 | |
| Days payables outstanding | 46.61 | 37.77 | 52.88 | 63.51 | 31.97 | |
| Days of inventory on hand | 75.54 | 107.59 | 114.7 | 147.19 | 51.5 | |
| Receivables turnover | 0.54 | 0.49 | 0.52 | 0.46 | 0.86 | |
| Payables turnover | 1.93 | 2.38 | 1.7 | 1.42 | 2.82 | |
| Inventory turnover | 1.19 | 0.84 | 0.78 | 0.61 | 1.75 | |
| ROE | 0.01 | 0.01 | 0.02 | 0.01 | 0.03 | |
| Capex per share | -0.67 | -0.68 | -1.48 | -0.84 | -0.51 |
4164.TW Frequently Asked Questions
What is CHC Healthcare Group stock symbol ?
CHC Healthcare Group is a TW stock and trading under the symbol 4164.TW
What is CHC Healthcare Group stock quote today ?
CHC Healthcare Group stock price is $58 today.
Is CHC Healthcare Group stock public?
Yes, CHC Healthcare Group is a publicly traded company.
Company Profile
- Volume Average 889.89K
- Market Capitalization 9.9B
- Employee 160
- CEO Mr. Yee-Min Jen
- Headquarters Taipei,TW
- IPO Date 2012-10-03
-
Website
https://www.chcg.com 
CHC Healthcare Group, together with its subsidiaries, provides a range of healthcare management services in Taiwan and internationally. It sells, installs, maintains, leases, and distributes medical equipment. The company is also involved in the provision of business management consultation and education training; elderly care business; and radiation sterilization business. In addition, it offers a range of equipment in the areas of radiation oncology, neurology, medical imaging, ophthalmology, and surgery. The company was founded in 1977 and is headquartered in Taipei, Taiwan.
